Picture of Icure Pharmaceutical logo

175250 Icure Pharmaceutical Income Statement

0.000.00%
kr flag iconLast trade - 00:00
Consumer DefensivesHighly SpeculativeSmall CapNeutral

Annual income statement for Icure Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue60,92290,14464,28359,36756,806
Cost of Revenue
Gross Profit18,21018,097-4,659-5,5801,298
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses67,301100,64896,69287,51181,702
Operating Profit-6,379-10,504-32,409-28,144-24,895
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-8,513-11,498-38,835-43,090-32,525
Provision for Income Taxes
Net Income After Taxes-8,654-12,150-38,384-42,549-32,299
Minority Interest
Net Income Before Extraordinary Items
Net Income-8,751-12,614-38,167-41,766-31,420
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income-8,751-12,614-38,167-41,766-31,420
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-412-664-1,423-1,753-799
Dividends per Share